Invion Pre-Tax Margin
Pre-Tax Profit Margin of Invion (IVX.AX) as of Sep 5, 2026.
Get this data via API
Financial Data API
Pre-Tax Margin
0.00
Last updated:
Pre-Tax Profit Margin of Invion is 2026 0.00 . Pre-Tax Profit Margin of Invion was 2025 -152.34 % . It decreases by % higher compared to the previous year.
The Invion Pre-Tax Margin history
3 Years
10 Years
25 Years
Max
Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2016
-3,479.04 AUD
Jan 1, 2018
-125.59 AUD
Jan 1, 2019
-65.59 AUD
Jan 1, 2020
-27.44 AUD
Jan 1, 2021
-63.65 AUD
Jan 1, 2022
-68.09 AUD
Jan 1, 2023
-39.34 AUD
Jan 1, 2024
-152.34 AUD
| YEAR | Pre-Tax Margin | YoY |
|---|---|---|
| -152.34 % | +287.23% | |
| -39.34 % | -42.22% | |
| -68.09 % | +6.98% | |
| -63.65 % | +131.98% | |
| -27.44 % | -58.17% | |
| -65.59 % | -47.78% | |
| -125.59 % | -96.39% | |
| -3,479.04 % | -45.56% | |
| -6,391.06 % | +150.63% | |
| -2,550.00 % | — |
Access this data via the Eulerpool API
Invion Stock analysis
What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Invion stock
On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Invion since 2006 – with annual values, charts, and detailed analysis.
Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Invion with sector peers and the industry average to assess whether it is attractive.
To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.
Access this data via the Eulerpool API
Margins — Invion
All Key Metrics — Invion
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth